Signal active
Organization
Contact Information
Overview
Grail develops a pan-cancer screening test designed to detect cancers at an early stage. Its pan-cancer screening test measures circulating nucleic acids in blood using high-intensity sequencing, population-scale clinical trials, enabling doctors to develop blood tests for early-stage cancer detection.
The company was founded in 2016 by Alex Aravanis and Jeff Huber in Menlo Park, California.
About
Biotechnology, Health Care, Medical, Medical Device, Health Diagnostics
2016
1001-5000
Headquarters locations
United States, North America
Social
N/A
Profile Resume
Grail headquartered in United States, North America, operates in the Biotechnology, Health Care, Medical, Medical Device, Health Diagnostics sector. The company focuses on Biotechnology and has secured $200.5B in funding across 100 round(s). With a team of 1001-5000 employees, Grail is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Grail, raised $100.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
5
8
0
$2004.7M
Details
5
Grail has raised a total of $2004.7M in funding over 5 rounds.
Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
---|---|---|---|---|
2020 | Late Stage Venture | 390.0M | ||
2016 | Seed | |||
2017 | Early Stage Venture | 1214.7M | ||
2016 | Early Stage Venture | 100.0M |
Investors
Grail is funded by 31 investors.
Investor Name | Lead Investor | Funding Round | Partners |
---|---|---|---|
Biomatics Capital Partners | - | FUNDING ROUND - Biomatics Capital Partners | 100.0M |
Google Ventures | - | FUNDING ROUND - Google Ventures | 100.0M |
Grail | - | FUNDING ROUND - Grail | 100.0M |
Longwood Fund | - | FUNDING ROUND - Longwood Fund | 100.0M |
Recent Activity
There is no recent news or activity for this profile.